• Mate Petricevic, Tomislav Kopjar, Bojan Biocina, Davor Milicic, Kresimir Kolic, Marko Boban, Bosko Skoric, Ante Lekic, and Hrvoje Gasparovic.
• Department of Cardiac Surgery, University of Zagreb School of Medicine-University Hospital Center Zagreb, Zagreb, Croatia.
• Thorac Cardiovasc Surg. 2015 Feb 1;63(1):2-20.

AbstractExcessive bleeding after cardiopulmonary bypass (CPB) operations remains to be a persistent problem and weak platelet function certainly contributes to bleeding diathesis. Antiplatelet therapy (APT) is an integral component of perioperative management in patients undergoing cardiac surgery procedures, both with and without use of CPB. In addition to individual variability in platelet function, different preoperative APT administration/discontinuation management further affects platelet function, which in turn may reflect bleeding tendency. However, the impact of drug-induced platelet inhibition on early postoperative bleeding extent remains difficult to predict. Herein, we reviewed the available evidence on the association between platelet function testing values and the extent of bleeding and transfusion requirements in early perioperative period. Currently, the association between platelet function measured by ex vivo assay and the occurrence of bleeding events remains uncertain. The intent of this review is to provide comprehensive literature insight into published evidence, investigating the possibility of platelet function tests to predict bleeding extent as well as transfusion requirements in cardiac surgery patients.Georg Thieme Verlag KG Stuttgart · New York.

13 keywords...

hide…